Disease · MONDO_0005417

wet macular degeneration

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. wet macular degeneration. Diseases, record MONDO_0005417. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005417

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: wet macular degeneration; Open Targets
Open Targets ID: MONDO_0005417; Open Targets
Other names: Kuhnt-Junius degeneration, choroidal neovascularization, exudative senile macular degeneration of retina, neovascular age-related macular degeneration, wet AMD, wet ARMD, wet age related macular degeneration, wet senile macular retinal degeneration; Open Targets
Disease Ontology: DOID:10873; Disease Ontology
MeSH: D057135; MeSH
Highest stage of its drugs: Approval, for 8 of its 55 drugs, from DailyMed, EMA Human Drugs, FDA and TTD; Open Targets

Drugs55

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AFLIBERCEPT	CHEMBL1742982	Protein	Approval	DailyMed and EMA Human Drugs	70	55	55	Drugs and targets
RANIBIZUMAB	CHEMBL1201825	Antibody	Approval	DailyMed and EMA Human Drugs	46	35	32	Drugs and targets
FARICIMAB	CHEMBL4297750	Antibody	Approval	EMA Human Drugs, FDA and TTD	18	14	14	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Approval	EMA Human Drugs	13	11	8	Drugs and targets
BROLUCIZUMAB	CHEMBL3707357	Antibody	Approval	EMA Human Drugs and TTD	13	11	11	Drugs and targets
PEGAPTANIB SODIUM	CHEMBL1201421	Small molecule	Approval	DailyMed and TTD	7	4	4	Drugs and targets
PEGPLERANIB SODIUM	CHEMBL3301576		Approval	TTD	4	2	0	Drugs and targets
VERTEPORFIN	CHEMBL5314346	Small molecule	Approval	DailyMed	4	2	2	Drugs and targets
ABICIPAR PEGOL	CHEMBL4297684	Protein	Phase 3	ClinicalTrials.gov	4	3	3	Drugs and targets
ALTEPLASE	CHEMBL1201593	Enzyme	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 55

See all 55 drugs

Targets52

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
VEGFA	VEGF-A mRNA	10	VEGF-A mRNA RNAi inhibitor; Vascular endothelial growth factor A antagonist; Vascular endothelial growth factor A inhibitor	Approval	https://conductscience.org/library/genes/7422	Drugs and targets
FLT1	VEGFR1 mRNA	4	VEGFR1 mRNA rnai inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
KDR	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	3	Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	3	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	2	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	2	Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5156	Drugs and targets
PGF	Placenta growth factor	2	Placenta growth factor inhibitor	Approval	https://conductscience.org/library/genes/5228	Drugs and targets
TLR3	Toll-like receptor 3	2	Toll-like receptor 3 activator	Phase 2	https://conductscience.org/library/genes/7098	Drugs and targets

1 to 10 of 52

See all 52 targets

Trials134

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01245387	Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration		1,001	2011-01-07	Macular Degeneration, Age-related Macular Degeneration, Neovascular Macular Degeneration	PEGAPTANIB SODIUM	Its record names the disease	ClinicalTrials.gov
NCT02462928	A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration	Phase 3	939	2020-07-28	Macular Degeneration	ABICIPAR PEGOL	Its record names the disease	ClinicalTrials.gov
NCT04005352	Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)	Phase 3	734	2024-01-30	Age-related Macular Degeneration	BROLUCIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03823287	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)	Phase 3	671	2022-05-04	Wet Macular Degeneration	AFLIBERCEPT, FARICIMAB	Its record names the disease	ClinicalTrials.gov
NCT03823300	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)	Phase 3	658	2022-05-04	Wet Macular Degeneration	AFLIBERCEPT, FARICIMAB	Its record names the disease	ClinicalTrials.gov
NCT01948830	Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD	Phase 3	650	2016-12-15	Age-related Macular Degeneration, Choroidal Neovascularization	RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03805100	Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD	Phase 3	582	2023-11-13	Macular Degeneration	RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03710564	Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections	Phase 3	535	2022-07-22	Age-Related Macular Degeneration	AFLIBERCEPT, BROLUCIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00460408	Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration		501	2012-12-11	Macular Degeneration	PEGAPTANIB SODIUM	Its record names the disease	ClinicalTrials.gov
NCT01006538	Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)	Phase 4	363	2019-07-22	Macular Degeneration	BEVACIZUMAB, RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 134

See all 134 trials

Comparisons in its trials30

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Brolucizumab 6 mg vs Aflibercept 2 mg: Number of Participants With Treatment Emergent Non-ocular Adverse Events (Greater Than or Equal to 2% in Any Treatment Arm) - Summary Table	182 of 366	185 of 368	734	NCT04005352	Trial comparisons
Arm A: Faricimab vs Arm B: Aflibercept: deaths from any cause	13 of 333	7 of 336	669	NCT03823287	Trial comparisons
Arm A: Faricimab vs Arm B: Aflibercept: serious adverse events	80 of 333	93 of 336	669	NCT03823287	Trial comparisons
Arm A: Faricimab vs Arm B: Aflibercept: deaths from any cause	10 of 331	14 of 326	657	NCT03823300	Trial comparisons
Arm A: Faricimab vs Arm B: Aflibercept: serious adverse events	91 of 331	101 of 326	657	NCT03823300	Trial comparisons
Group I Ranibizumab 0.5 mg TER vs Group II Ranibizumab 0.5 mg Monthly: serious adverse events	39 of 323	42 of 326	649	NCT01948830	Trial comparisons
Xlucane (Proposed Ranibizumab Biosimilar) vs Lucentis (Ranibizumab): deaths from any cause	8 of 292	3 of 290	582	NCT03805100	Trial comparisons
Xlucane (Proposed Ranibizumab Biosimilar) vs Lucentis (Ranibizumab): serious adverse events	33 of 292	35 of 290	582	NCT03805100	Trial comparisons
Arm A: Epimacular Bracytherapy + Lucentis® vs Arm B: Lucentis® Only: Percentage of Subjects Gaining ≥ 15 ETDRS Letters	3 of 244	6 of 119	363	NCT01006538	Trial comparisons
Arm A: Epimacular Bracytherapy + Lucentis® vs Arm B: Lucentis® Only: Percentage of Subjects Gaining ≥ 0 ETDRS Letters	91 of 244	55 of 119	363	NCT01006538	Trial comparisons

1 to 10 of 30

See all 30 comparisons in its trials

Papers from its trials133

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38461841	RESULT	1	PubMed
38382813	RESULT	2	PubMed
38123670	RESULT	1	PubMed
38040055	RESULT	1	PubMed
37535382	RESULT	2	PubMed
36977322	RESULT	1	PubMed
36399178	RESULT	1	PubMed
36246941	RESULT	3	PubMed
35822428	RESULT	1	PubMed
35511286	RESULT	1	PubMed

1 to 10 of 133

See all 133 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005417

GET https://conductscience.org/api/diseases/v1/MONDO_0005417/drugs?page=2

API reference For AI assistants